- What are BXQ-350 nanovesicles?
- Do BXQ-350 nanovesicles really work for treating cancer?
- How is BXQ-350 nanotherapy different from other types of cancer therapy?
- When will BXQ-350 nanovesicles be available for treating cancer patients?
- What can be done to speed the development and availability of BXQ-350
nanovesicles for treating cancer patients?
- What other ways can BXQ-350 nanovesicles be used for innovation?
- Why aren’t other big drug companies working on these nanovesicles?
- How can I invest in Bexion Pharmaceuticals’ new anti-cancer therapies?
- Who are Bexion Pharmaceuticals’ management team leaders?
- Who are Bexion Pharmaceuticals’ board of directors?
1. What are BXQ-350 nanovesicles?
BXQ-350 nanovesicles are tiny lipid micro-bubbles (dioleoylphosphatidylserine =
DOPS) that contain a unique human protein (saposin C = SapC). In the body, BXQ-350
nanovesicles stick only to cancer cell’s membrane and increase natural cell death
(apoptosis) of the cancer cell. Treatment of cancer with BXQ-350 nanovesicles in
animal models shows a high safety margin, because it uniquely causes natural cell
death of cancer cells and does not appear to affect any healthy cells in the body.
2. Do BXQ-350 nanovesicles really work for treating cancer?
New research findings on BXQ-350 nanovesicles for the diagnosis and treatment of
cancer are very promising. The tumor targeting and anti-cancer activities of BXQ-350
nanovesicles were discovered and first published by researchers at Cincinnati Children’s
Hospital Medical Center 1. These researchers showed that BXQ-350 nanovesicles killed
human brain, nerve, and breast cancer cells in test tubes. They also showed that
BXQ-350 nanovesicles were able to treat human brain and nerve cancers transplanted
into mice with no adverse effects after 5 weeks of dosing.
Additional unpublished research sponsored by Bexion Pharmaceuticals has shown that
BXQ-350 nanovesicles kill over 60 different types of human cancer cells in test
tubes. By adding a dye to BXQ-350 nanovesicles, the Bexion scientists have been
able to visualize penetration of the drug into several different types of cancers
in rats and mice including pancreatic, breast, and brain cancers, allowing them
to be uniquely visualized. Of importance, BXQ-350 treatment significantly increased
(doubled) survival times and rescued many mice with either brain or pancreatic
cancer. Four out of six mice with pancreatic cancer survived with BXQ-350 treatment.
In total, BXQ-350 nanovesicles have been shown to be highly effective for treating
cancer in 7 different mouse cancer models. In these extensive pre-clinical (animal)
studies, there have been no observed adverse effects on animal behavior, body weight,
feed consumption, organ weights, clinical pathology blood tests, or tissue pathology.
Clinical trials will determine efficacy and safety in humans.
3. How is BXQ-350 nanotherapy different from other types of cancer therapy?
BXQ-350 targets what appears to be a ubiquitous marker on tumor cell surfaces that
is increasingly being recognized by the scientific and medical community. Attacking
a general feature of cancers is expected to result in broader efficacy than current
“targeted” therapies. Moreover, treatment of cancer with BXQ-350 nanovesicles in
animal models has shown a high safety margin, because it uniquely causes natural
cell death of cancer cells and does not appear to affect any healthy cells in the
body. Bexion hopes that BXQ-350 nanotherapy will be effective for treating many
different kinds of cancer in people without any debilitating or embarrassing side
effects commonly associated with cancer chemotherapy.
4. When will BXQ-350 nanovesicles be available for treating cancer patients?
Clinical research in cancer patients is being planned, and the first-in-human phase
I research studies are scheduled to begin in 2013. Product commercial availability
will depend on successful clinical test results in cancer patients and regulatory
5. What can be done to speed the development and availability of BXQ-350 nanovesicles
for treating cancer patients?
With outstanding potential to increase survivability and reduce the extensive medical
and societal costs associated with cancer world-wide, there is much interest in
developing the BXQ-350 nanovesicle technology as rapidly as possible.
The National Cancer Institute recently increased funding of Bexion’s BXQ-350 nanotherapy
development program and selected Bexion Pharmaceuticals as a collaborative research
partner to help advance BXQ-350 rapidly as a treatment for cancer.
6. What other ways can BXQ-350 nanovesicles be used for innovation?
The BXQ-350 nanovesicles are also useful for delivering imaging agents (e.g. dyes, or other imaging agents)
into cancers that can help cancer specialists (oncologists) visualize and detect
cancer very early2. The ability to stick only to cancer cells also makes BXQ-350
nanovesicles an exciting new tumor-targeting tool for early diagnosis of cancer
and as a highly effective vehicle for targeted delivery of other anti-cancer drugs.
7. Why aren’t other big drug companies working on these nanovesicles?
The BXQ-350 technology is proprietary and protected by several patents and intellectual
property laws. Bexion Pharmaceuticals has licensed the rights for exclusive development
of the BXQ-350 technology, and is constantly working to further protect the technology.
Bexion Pharmaceuticals is the ideal company to bring this exciting new anti-cancer
approach to cancer patients world-wide as quickly as possible. As an innovative,
small, and nimble company, Bexion is optimally positioned to develop and obtain
global market approvals for this promising new technology. Though still in the early
stages of development, there is rapidly growing interest and enthusiasm among oncologists
and thought-leaders world-wide on the development of BXQ-350 nanotherapy for cancer.
8. How can I invest in Bexion Pharmaceuticals’ new anti-cancer therapies?
Bexion is a private limited liability corporation that is currently not traded publicly
on a stock market exchange. There are several ways for individuals or organizations
to invest or partner with Bexion Pharmaceuticals for the development of BXQ-350
nanotherapy. These include:
- Collaborative research partnerships for product development
- Innovative investment options
- Research grants
For details on how to invest or partner with Bexion, please use the
Contact Us page.
9. Who are Bexion Pharmaceuticals’ management team leaders?
Bexion was founded in 2006 by pharma industry veterans, led by Dr. Ray Takigiku.
Bexion is focused on the development and commercialization of innovative cures for
View Management Team
10. Who are Bexion Pharmaceuticals’ board of directors?
Bexion’s board of directors is a diverse group of highly experienced business entrepreneurs
and healthcare professionals.
View Board of Directors
- Qi X., Chu Z., Mahller Y., Stringer K., Witte D., Cripe T. Cancer-selective targeting
and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res.
15(18): 5840-5851, 2009.
- Kaimal V, Chu Z, Mahller YY, Papahadjopoulos-Sternberg B, Cripe TP, Holland SK,
Q Xi. Saposin C Coupled Lipid Nanovesicles Enable Cancer-Selective Optical and Magnetic
Resonance Imaging Molecular Imaging and Biology. (On-line 14 September
2010), pp. 1-12-12.